Gas relief drug may skew stomach bug tests, new study warns
NCT ID NCT07293234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study will check if simethicone, a medicine used to reduce gas during endoscopy, makes it harder to detect H. pylori bacteria. About 100 adults with a positive H. pylori test will take simethicone or a placebo before their procedure. The goal is to see if the drug lowers detection rates, which could change how doctors prepare patients for testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 79 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Age ≥18 years and \<80 years * Rapid Urease Test (RUT) positive on endoscopic gastric biopsy * Ability to provide informed consent Exclusion Criteria * Use of antibiotics or bismuth compounds within 4 weeks prior to enrollment * Use of proton pump inhibitors (PPIs) within 2 weeks prior to enrollment * Use of H2 receptor blockers within 72 hours prior to enrollment * History of previous gastric surgery * Current anticoagulation therapy * Severe thrombocytopenia (platelet count \<50,000/mm³) * Severe comorbidities that contraindicate the administration of sedation * Immunodeficiency * Pregnancy * Negative initial Rapid Urease Test (RUT) * Inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for H.pylori infection are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Two-Drug combo shows promise against stomach bug
- Which test is better for detecting h. pylori?
- New stomach bug treatment shows promise in 14-Day trial
- Stomach bug treatment may lower bleeding risk for heart patients
- Scientists map h. Pylori's resistance to antibiotics
- Argon plasma zaps stomach bugs in new trial